CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform that the Nomination and Remuneration Committee of the Board of Directors of the Company at their meeting held on February 3, 2022, has allotted 20,000 equity shares of face value Rs. 2/- each, to the employees of the Company and its subsidiaries, upon exercise of stock options under Employee Stock Options Scheme(s) of the Company. Q3FY22 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Pharmaceuticals and Biotechnology company Caplin Point Laboratories announced Q3FY22 results: Q3FY22 Revenue at Rs. 336 crore, up 19.8% YoY, as compared to Rs. 280 crore in Q3 FY21 Gross Margins improved to 55.9% in Q3FY22 from 54.8% in Q3FY21 PAT increased by 24.0% to Rs. 228 crore in 9MFY22 as against Rs.184 crore in 9MFY21 PAT for the quarter is at Rs. 79 crore up 20% as compared to Rs. 66 crore in Q3FY21 Cash flow From Operations at Rs 224 crore in 9MFY22 as against Rs 266 crore for the whole year FY21 Basic EPS grew by 25% to Rs. 29.18 in 9MFY22 against Rs. 23.25 in 9MFY21 (not Annualized) With continued focus on Cash Flow, Receivables sustained at 94 days despite growth in sales Inventory stood at Rs. 207 crore (including transit inventory of Rs.83 crore) in Dec 21 as against Rs. 237 crore in Sep 21. Considering the extended transit time and with a focus on need to keep Inventory closer to customers, the current level of inventory is likely to continue in Q4 as well. Geographical breakup of sales for 9MFY22: LATAM & ROW - 91%, US – 9% Result PDF CAPLIN POINT LABORATORIES LTD. - 524742 - Results - Financial Results For The Quarter And Nine Months Ended December 31, 2021.
Further to our intimation dated January 28, 2022, we wish to inform you that the Board of Directors of the Company at its meeting held today has, inter-alia approved the Un-audited standalone and consolidated financial results and the Limited Review Report (Annexure-1) of the Company as per Indian Accounting Standards for the quarter and nine months ended December 31, 2021. We also enclose a Press Release issued by the Company (Annexure 2) and an investor presentation in this regard (Annexure 3). The meeting commenced at 11:00 A.M and concluded at 12:45 P.M. Kindly take the same on your records. CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Compliance under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015 CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Intimation for Board Meeting Intimation
CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company will be held on Thursday, February 3, 2022, to consider and approve, inter-alia the standalone and consolidated un-audited financial results of the Company, for the quarter and nine months ended December 31, 2021. This intimation is being given in compliance with the provisions of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As informed earlier vide our letter dated December 28, 2021, the trading window for dealing in the Company''s scrips by the Directors and Designated Employees of the Company will remain closed from January 1, 2022 to February 5, 2022 (both days inclusive), in terms of the Company''s Code of Conduct to regulate, monitor and report trading by insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015. CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015 CAPLIN POINT LABORATORIES LTD. - 524742 - Shareholding for the Period Ended December 31, 2021
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here CAPLIN POINT LABORATORIES LTD. - 524742 - Transfer Of Unclaimed Dividend/ Equity Shares To Investor Education And Protection Fund (IEPF) Account
Transfer of unclaimed dividend/ equity shares to Investor Education and Protection fund (IEPF) Account CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015